Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

This study has been terminated.
(Part A, the dose escalation and primary objective of the study, was completed. Part B, the dose expansion, was not conducted due to a business decision.)
Information provided by (Responsible Party):
Amgen Identifier:
First received: April 22, 2010
Last updated: March 2, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2014
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)